Open access
Nov 2026
Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations.
BACKGROUND Despite improved outcomes with immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC), reliable biologically-driven prognostic markers remain needed. The CHOMET study evaluated tumor ABCA1/ABCG1 expression and their association with systemic lipid parameters, nutritional sta...
G. C. Giudice, Hassan M. Abushukair, G. Mazzaschi et al.
· The Oncologist · 0 citations